Pulse Biosciences (NASDAQ:PLSE) Lifted to “Sell” at StockNews.com

Pulse Biosciences (NASDAQ:PLSE) was upgraded by analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Friday.

Pulse Biosciences Trading Down 4.6 %

Shares of NASDAQ PLSE opened at $17.87 on Friday. The business’s 50 day moving average is $17.63 and its 200-day moving average is $12.63. The firm has a market cap of $986.87 million, a P/E ratio of -22.06 and a beta of 1.75. Pulse Biosciences has a 1-year low of $3.78 and a 1-year high of $22.69.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds have recently bought and sold shares of PLSE. BNP Paribas Financial Markets grew its position in shares of Pulse Biosciences by 63.6% during the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after purchasing an additional 2,952 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Pulse Biosciences in the first quarter valued at approximately $88,000. Quest Partners LLC acquired a new stake in Pulse Biosciences during the second quarter worth approximately $91,000. Cetera Advisors LLC bought a new position in Pulse Biosciences during the 1st quarter worth $109,000. Finally, PNC Financial Services Group Inc. acquired a new position in Pulse Biosciences in the 4th quarter valued at $242,000. 76.95% of the stock is owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.